What is the difference between cagrilintide and eloralintide?

Both are long-acting amylin analogs built for weekly dosing with a fatty acid chain that binds albumin, but they target receptors differently. Cagrilintide, from Novo Nordisk, was designed to activate both amylin and calcitonin receptors. Eloralintide, from Eli Lilly, favors the AMY1 amylin receptor by about 12-fold over the calcitonin receptor in cell assays with human receptors.

The working idea is that leaning away from the calcitonin receptor could mean fewer stomach effects, but no head-to-head trial has tested it. Both are investigational, and neither is FDA approved. Their partners differ too: cagrilintide is paired with semaglutide in CagriSema, while eloralintide is being tested with tirzepatide. Our eloralintide explainer compares them side by side. Shop eloralintide for receptor selectivity research.